Focus for BIO 2008
Genesis' long-term value proposition lies in its commitment to innovation in research and development and commercializing novel sciences. We place high priority on establishing and cultivating productive collaborations with industry partners, thereby fast-tracking the product development process and sharing risks and rewards with partners.
Genesis is interested in out-licensing or partnering on:
- siRNA therapeutics for oncology, targeting nutrient uptake and energy production
- Zyrogen for bone and autoimmune disease
- MED-1 for tuberculosis
